CClinicalTrials.gg
CompletedNCT05263427MOMAUpdated Dec 8, 2025

Maternal-Fetal Monitoring by Connected Abdominal Patch - MOMA

An interventional study of TOCONAUTE in Obstetrical Complications and Monitoring Injury of Scalp of Newborn, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

During a previous clinical trial (RCF-abdo: 2018-A01194-51), trans-abdominal signals were collected in 90 patients at the maternity Jeanne de Flandre. This database allowed us to develop a new medical device able to measure in real time and continuously the fetal heart rate and the uterine contractions.

The goal here is to assess the performance of the device in real situation during labour.

This study will be carried out in the maternity labor ward in CHU Lille, France.

The TOCONAUTE will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.

For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient.

02

Conditions studied

  • Obstetrical Complications
  • Monitoring Injury of Scalp of Newborn

Keywords

  • Fetal Heart Rate
  • Monitoring
  • Uterine contraction
  • Electrocardiogram
03

In context

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pregnant woman in labor
  • Singleton
  • Cephalic presentation

Exclusion criteria

Exclusion Criteria:

  • Hospitalisation for a medical termination of pregnancy
  • Death in utero
  • Multiple pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    TOCONAUTE and gold standard : cardiotocograph

    Device: TOCONAUTE

Interventions

  • DeviceTOCONAUTE

    This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph. For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient.

    Also known as: foetal heart rate and uterine contractions recording

06

What researchers measure

Primary outcomes

  1. Fetal heart rate with the TOCONAUTE

    The fetal heart rate from the our device will be averaged on 3 beats and resampled at 4Hz to be comparable to the fetal heart rate from the cardiotocograph. Both of the signals will be resynchronized and compared sample by sample with a Pearson's correlation test. Measure of the fetal heart rate with the TOCONAUTE compared to the measure of the fetal heart rate with a cardiotocograph.

    Time frame: 1 year

Secondary outcomes

  1. Uterine contractions with the TOCONAUTE according to the different phase of labor.

    Measure of the uterine contractions with the TOCONAUTE compared to the measure of the uterine contractions with a cardiotocograph according to the different phase of labor. Both signals of the uterine contractions will be resynchronized and compared sample by sample with a Pearson's correlation test.

    Time frame: 1 year

  2. Maternal heart rate with the TOCONAUTE

    Measure of the maternal heart rate with the TOCONAUTE compared to the measure of the maternal heart rate with a cardiotocograph. Both signals of the maternal heart rate will be resynchronized and compared sample by sample with a Pearson's correlation test.

    Time frame: 1 year

  3. Fetal heart rate with the TOCONAUTE according to the different phase of labor.

    Measure of the fetal heart rate with the TOCONAUTE compared to the measure of the fetal heart rate with a cardiotocograph according to the different phase of labor.

    Time frame: 1 year

  4. Fetal stress index (Heart rate variability index reflecting parasympathetic fluctuation)

    Feasibility of the measure of the Fetal stress index (Heart rate variability index reflecting parasympathetic fluctuation)

    Time frame: 1 year

07

Study locations

1 site
  • Hop Jeanne de Flandre Chu Lille
    Lille, 59037, France
08

References and documents

Publications

  • Wojtanowski A, Garabedian C, Charlier P, Prot P, Ghesquiere L, De Jonckheere J. Intrapartum monitoring of the fetal heart rate using transabdominal electrocardiography: A reliability and accuracy study. J Gynecol Obstet Hum Reprod. 2025 May;54(5):102942. doi: 10.1016/j.jogoh.2025.102942. Epub 2025 Mar 16. PubMed 40101837 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05263427
Lead sponsor
University Hospital, Lille
Collaborators
Clinical Investigation Centre for Innovative Technology Network, BioSerenity, National Research Agency, France
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Aug 31, 2022
Primary completion
Nov 3, 2023
Completion
Nov 3, 2023
Last update
Dec 8, 2025

Study contacts

Charles Garabedian, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion